Compare CDNA & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | NNNN |
|---|---|---|
| Founded | 1998 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2007 | N/A |
| Metric | CDNA | NNNN |
|---|---|---|
| Price | $24.08 | $14.88 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 652.3K | 17.5K |
| Earning Date | 04-28-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $48,324,000.00 | N/A |
| Revenue This Year | $16.01 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | $469.20 | ★ $446.57 |
| Revenue Growth | ★ 18.93 | N/A |
| 52 Week Low | $10.96 | $8.59 |
| 52 Week High | $24.02 | $55.65 |
| Indicator | CDNA | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 65.75 | 28.52 |
| Support Level | $15.80 | $10.50 |
| Resistance Level | N/A | $31.12 |
| Average True Range (ATR) | 1.04 | 3.79 |
| MACD | 0.09 | -1.99 |
| Stochastic Oscillator | 93.00 | 5.17 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).